Establishment and characterization of a new activated B-cell-like DLBCL cell line, TMD12

Diffuse large B-cell lymphoma (DLBCL) is an essentially heterogeneous subgroup of aggressive B-cell lymphomas. To categorize the entity based on the “cell-of-origin” (COO), gene expression profiling studies have classified DLBCL into three subtypes with different clinical outcomes: the activated B-cell-like (ABC) subtype, the germinal center B-cell-like (GCB) subtype, and an unclassified subtype [1, 2]. Patients with ABC-DLBCL exhibit a rela tively refractory clinical course compared to others when treated with the standard regimen, rituximab-CHOP [1, 2].

Source: Experimental Hematology - September 30, 2022 Category: Hematology Authors: Toshikage NAGAO, Kota YOSHIFUJI, Daichi SADATO, Yotaro MOTOMURA, Makiko SAITO, Kurara YAMAMOTO, Kouhei YAMAMOTO, Ayako NOGAMI Source Type: research